Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial

Table 6 Hazard ratio’s for fluoroquinolones during admission

	Working diagnosis of CAP N = 2107; 146 n/w cardiac events		Radiologically proven CAP N = 1604; 115 n/w cardiac events
Outcome antibiotic	Crude HR (CI)	Adjusted HR (CI)	Crude HR (CI)	Adjusted HR (CI)
n/w cardiac event
ciprofloxacin	0.77 (0.43;1.37)	0.70 (0.39;1.26)	0.81 (0.44;1.50)	0.72 (0.39;1.33)
levofloxacin	0.40 (0.18;0.87)	0.43 (0.20;0.93)	0.33 (0.12;0.91)	0.36 (0.13;0.98)
moxifloxacin	0.56 (0.36;0.87)	0.56 (0.36;0.88)	0.53 (0.32;0.86)	0.54 (0.33;0.89)
n/w Heart failure
ciprofloxacin	0.71 (0.36;1.44)	0.65 (0.32;1.31)	0.71 (0.34;1.50)	0.62 (0.29;1.31)
levofloxacin	0.25 (0.08;0.80)	0.27 (0.08;0.86)	0.12 (0.02;0.85)	0.12 (0.02;0.88)
moxifloxacin	0.48 (0.27;0.84)	0.50 (0.28;0.87)	0.43 (0.23;0.81)	0.46 (0.24;0.85)
n/w Arrhythmia
ciprofloxacin	0.83 (0.32;2.12)	0.75 (0.29;1.93)	0.73 (0.25;2.09)	0.64 (0.22;1.86)
levofloxacin	0.50 (0.15;1.64)	0.49 (0.15;1.62)	0.71 (0.21;2.39)	0.70 (0.21;2.35)
moxifloxacin	0.66 (0.33;1.34)	0.66 (0.33;1.34)	0.69 (0.32;1.46)	0.71 (0.33;1.51)

n/w = new or worsening
Hazard ratio’s (HR’s) with 95% confidence intervals (CIs) from Cox PH models for time-dependent exposure to different fluoroquinolones during admission on cardiac events. Adjusted HR’s are adjusted for confounders mentioned in Methods

ISSN: 1471-2334